Effect of canrenone and amiloride on the prooxidative effect induced by aldosterone in human mononuclear leukocytes in vitro

Journal of Endocrinological Investigation

Volumn 32, Issue 11, 2009, Pages 895-898

  Fiore, C ^a   Sartorato, P ^a   Pagnin, E ^a   Ragazzi, E ^a   Calo L A ^a   Armanini, D ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Aldosterone; Amiloride; Canrenone; Mineralocorticoid receptors; Oxidative stress

Indexed keywords

ALDOSTERONE; AMILORIDE; CANRENONE; P22 PHOX PROTEIN; PROTEIN SUBUNIT; UNCLASSIFIED DRUG;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CELL ISOLATION; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MONONUCLEAR CELL; NORMAL HUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN ISOLATION; WESTERN BLOTTING;

ADULT; ALDOSTERONE; ALDOSTERONE ANTAGONISTS; AMILORIDE; CANRENONE; FEMALE; HUMANS; HYDROCORTISONE; LEUKOCYTES, MONONUCLEAR; MALE; NADPH OXIDASE; SODIUM CHANNEL BLOCKERS;

EID: 77649202363     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/6299     Document Type: Article

References (31)

1. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002, 143: 4828-36.
2. Karram T, Abbasi A, Keidar S, et al. Effects of spironolactone and eposartan on cardiac remodelling and angiotensin-converting enzyme isoforms in rats with experimental heart failure. Am J Physiol Heart Circ Physiol 2005, 289: H1351-8.
3. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341: 709-17.
4. Pitt B, Remme W, Zannad F, et al; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone a selective aldosterone blocker in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348: 1309-21.
5. Weber KT, Anversa P, Armstrong PW, et al. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol 1992, 20: 3-16.
6. Yasunari K, Maeda K, Nakamura M, Yoshikawa J. Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose, and C-reacting protein. Hypertension 2002, 39: 777-80.
7. Gerling IC, Sun Y, Ahokas RA, et al. Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype. Am J Physiol Heart Circ Physiol 2003, 285: H813-21.
8. Mervaala EM, Muller DN, Park JK, et al. Monocyte infiltration and adhesion molecules in a rat model of high renin hypertension. Hypertension 1999, 33: 389-95.
9. Sun Y, Zhang J, Lu L, et al. Aldosterone-induced inflammation in the rat heart. Role of oxidative stress. Am J Pathol 2002, 161: 1773-81.
10. Keidar S, Hayek T, Kaplan M, et al. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and arteriosclerosis in apolipoprotein-E deficient mice. J Cardiovasc Pharmacol 2003, 41: 955-63.
11. Keidar S, Kaplan M, Pavlotzky E, et al. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 2004, 109: 2213-20.
12. Takai S, Jin D, Muramatsu M, et al. Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension 2005, 46: 1135-9.
13. Park YM, Park MY, Suh YL, Park JB. NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats. Biochem Biophys Res Commun 2004, 313: 812-7.
14. Armanini D, Strasser T, Weber PC. Characterization of aldosterone binding sites in circulating human mononuclear leucocytes. Am J Physiol 1985, 248: E388-90.
15. Wehling M, Armanini D, Strasser T, Weber PC. Effect of aldosterone on sodium and potassium concentration in human mononuclear leucocytes. Am J Physiol 1987, 252: E505-8.
16. Wehling M, Kuhls S, Armanini D. Volume regulation of human lymphocytes by aldosterone in isotonic media. Am J Physiol 1989, 20: E170-4.
17. Calò LA, Zaghetto F, Pagnin E, et al. Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22(phox) in human mononuclear leukocytes. J Clin Endocrinol Metab 2004, 89: 1973-6.
18. Haddad JJ. Amiloride and the regulation of NF-κB: an unsung crosstalk and missing link between fluid dynamics and oxidative stress-related inflammation-controversy or pseudocontroversy? Biochem Biophys Res Commun 2005, 327: 373-81.
19. Garciandia A, López R, Tisaire J, et al. Enhanced Na(+)-H+ exchanger activity and NHE-1 mRNA expression in lymphocytes from patients with essential hypertension. Hypertension 1995, 25: 356-64.
20. De Vito P. The sodium/hydrogen exchanger: a possible mediator of immunity. Cell Immunol 2006, 240: 69-85.
21. Bubien JK, Warnock DG. Amiloride-sensitive sodium conductance in human B lymphoid cells. Am J Physiol 1993, 265: C1175-83.
22. Ottaviani E, Franchini A, Mandrioli M, Saxena A, Hanukoglu A, Hanukoglu I. Amiloride-sensitive epithelial sodium channel sub-units are expressed in human mussel immunocytes. Dev Comp Immunol 2002, 26: 395-402.
23. Bellocq A, Suberville S, Philippe C, et al. Low environmental pH is responsible for the induction of nitric-oxide synthase in macrophages. J Biol Chem 1998, 273: 5086-92.
24. Friedman M. The use of ranks to avoid the assumption of normality implicit in the analysis of variance. J Am Stat Assoc 1937, 32: 675-701.
25. Wilcoxon F. Individual comparisons by ranking methods. Biometrics 1945, 1: 80-3.
26. Michea L, Delpiano AM, Hitschfeld C, Lobos L, Lavandero S, Marusic ET. Eplerenone blocks nongenomic effects of aldosterone on the Na+/H+ exchanger, intracellular Ca2+ levels, and vaso-constriction in mesenteric resistance vessels. Endocrinology 146, 3: 973-80.
27. Fiebeler A, Luft FC. The mineralocorticoid receptor and oxidative stress. Heart Fail Rev 2005, 10: 47-52.
28. Piwien-Pilipuk G, Ayala A, Machado A, Galigniana D. Impairment of mineralocorticoid receptor (MR)-dependent biological response by oxidative stress and aging: correlation with post-translational modification of MR and decreased ADP-ribosylatable level of elongation factor 2 in kidney cells. J Biol Chem 2002, 277: 11896-903.
29. Calò LA, Armanini D. Aldosterone and thrombosis formation: implications for ischemic and atherosclerotic heart disease. J Endocrinol Invest 2006, 29: 675-6.
30. Armanini D, Scaroni C, Mattarello MJ, Fiore C, Albiger N, Sartorato P. Idiopathic primary hyperaldosteronism: normalization of plasma aldosterone after one month withdrawal of long-term therapy with aldosterone-receptor antagonist potassium canrenoate. J Endocrinol Invest 2005, 28: 236-40.
31. Ma J, Albornoz F, Yu C, Byrne DW, Vaughan DE, Brown NJ. Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolitic balance. Hypertension 2005, 46: 313-20.